TransThera Sciences (HKG:2617) narrowed its attributable loss to 122.9 million yuan in the first half of 2025 from 160.4 million yuan a year prior, a Monday Hong Kong bourse filing said.
Loss per share for the clinical-stage biopharmaceutical firm was 0.32 yuan, down from 0.42 yuan in the year-ago period.
The firm did not record revenue in the period.
Other income and gains, on the other hand, fell 65.1% to 3.6 million yuan in the six months from 10.4 million yuan a year prior, mainly due to a lower interest income from bank deposits and wealth management products, as well as a decline in government grants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.